Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).

Abstract:

:In studies conducted by the Eastern Cooperative Oncology Group, treatment with either paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) or carboplatin was associated with an improvement in 1-year survival in patients with stage IV non-small cell lung cancer (NSCLC). Based on these findings, a phase II trial of carboplatin plus paclitaxel was conducted in patients with advanced NSCLC to determine the activity and toxicity of this regimen. Eligibility requirements included stage IIIB or IV histologically confirmed NSCLC, Eastern Cooperative Oncology Group performance status of 0 to 2, no prior chemotherapy, and adequate hematologic, renal, hepatic, and cardiac functions. Paclitaxel was administered intravenously over 24 hours at a dose of 135 mg/m2 (28 patients) or 175 mg/m2 (23 patients), followed by a 1-hour infusion of carboplatin on day 2. Carboplatin was administered at a dose of 300 mg/m2 (16 patients) or, using the Calvert formula, a dose calculated to achieve an area under the concentration-time curve of 6 mg/mL x min (35 patients). Treatment was repeated every 28 days for a total of six cycles. Among the 51 eligible patients, 34 were men and 17 were women; their median age was 60 years and their median Eastern Cooperative Oncology Group performance status was 1. Six patients had stage IIIB and 45 had stage IV disease. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3% of treatment cycles, respectively. The most common nonhematologic toxicities noted included nausea and emesis, neuropathy, and arthralgia and myalgia. There were no complete responses and 14 partial responses, for an overall response rate of 27% (95% confidence interval, 17% to 41%). Median survival was 38 weeks and the survival rate at 1 year was 32%. Paclitaxel plus carboplatin, as given in this study, was found to be a moderately active regimen in patients with advanced NSCLC. This regimen warrants comparison with existing cisplatin-based regimens in a prospective randomized trial.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Johnson DH,Paul DM,Hande KR,DeVore R

subject

Has Abstract

pub_date

1996-12-01 00:00:00

pages

42-6

issue

6 Suppl 16

eissn

0093-7754

issn

1532-8708

journal_volume

23

pub_type

临床试验,杂志文章
  • Cardio-oncology in clinical studies and real life.

    abstract::Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the i...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2019.01.004

    authors: Dent SF,Suter TM,López-Fernández T,Opolski G,Menna P,Minotti G

    更新日期:2019-12-01 00:00:00

  • Acute promyelocytic leukemia: recent advances in diagnosis and management.

    abstract::Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RARalpha), and leading to a blockage in the differentiation of the granulocytic cells. The accumulation of the promyelocytic blasts in the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2008.04.010

    authors: Lo-Coco F,Ammatuna E,Montesinos P,Sanz MA

    更新日期:2008-08-01 00:00:00

  • Cardiac testing to manage cardiovascular risk in cancer patients.

    abstract::Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.01.003

    authors: Davis M,Witteles RM

    更新日期:2013-04-01 00:00:00

  • Trans-retinoic acid and related differentiation agents.

    abstract::Interest in retinoids as therapeutic agents has developed as a result of the observations of remission induction with all-trans retinoic acid (tRA) in patients with acute promyelocytic leukemia (APL), and of high objective response rates noted with the combination of cis-retinoic acid (cRA) with interferon-alpha in sq...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Parkinson DR,Smith MA,Cheson BD,Stevenson HC,Friedman MA

    更新日期:1992-12-01 00:00:00

  • Phase II and III studies with carboplatin in small cell lung cancer.

    abstract::Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gatzemeier U,Hossfeld DK,Neuhauss R,Reck M,Achterrath W,Lenaz L

    更新日期:1992-02-01 00:00:00

  • Recent updates on the role of chemotherapy in pancreatic cancer.

    abstract::Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of g...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.06.022

    authors: Burris HA 3rd

    更新日期:2005-08-01 00:00:00

  • Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally thought of as relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Glantz MJ,Choy H,Akerley W,Kearns CM,Egorin MJ,Rhodes CH,Cole BF

    更新日期:1996-12-01 00:00:00

  • Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

    abstract::The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kosmidis PA,Samantas E,Fountzilas G,Pavlidis N,Apostolopoulou F,Skarlos D

    更新日期:1994-06-01 00:00:00

  • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.

    abstract::In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00284-7

    authors: Le Chevalier T

    更新日期:2003-08-01 00:00:00

  • Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study.

    abstract::The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for pre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rosenthal DI,Sinard RJ,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Griener J,Frenkel EP,Carbone DP

    更新日期:1997-12-01 00:00:00

  • Topotecan in advanced colorectal cancer.

    abstract::Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Creemers GJ

    更新日期:1997-12-01 00:00:00

  • Clinical pharmacokinetics of fluorouracil and folinic acid.

    abstract::This article deals with the pharmacokinetics of fluorouracil (5-FU) and folinic acid (CHO-THF). 5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes. The high body clearance is mainly caused by a rapid catabolism of 5-FU to dihydrofluorouracil (FUH2), alpha-fluoro-ureidopropionic acid (F...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schalhorn A,Kühl M

    更新日期:1992-04-01 00:00:00

  • Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

    abstract::The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

    更新日期:1985-03-01 00:00:00

  • New approaches to treating malignances with stem cell transplantation.

    abstract::Stem cell transplantation has been successfully used to treat a wide variety of hematologic malignancies. New and exciting strategies being developed for use in conjunction with transplant will be useful in overcoming tumor resistance. It is now clear that a significant part of the antitumor effect of allogeneic stem ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Margolis J,Borrello I,Flinn IW

    更新日期:2000-10-01 00:00:00

  • Farnesyltransferase inhibitors.

    abstract::The targeting of molecular abnormalities in neoplasms may provide an opportunity to improve the selectivity of cancer therapy. Ras mutations are a common genetic event in human cancers. Other genetic changes in tumors can signal through ras-dependent pathways as well. The targeting of ras through the inhibition of Ras...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90286-6

    authors: Hahn SM,Bernhard E,McKenna WG

    更新日期:2001-10-01 00:00:00

  • Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

    abstract::Docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) is highly effective in the first-line treatment of metastatic breast cancer, achieving an objective response rate of 61% (95% confidence interval, 52% to 69%). This rate of response is seen in patients with poor prognostic factors such as liver metastases and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Trudeau ME

    更新日期:1999-06-01 00:00:00

  • THe genetics of familial breast cancer.

    abstract::Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cannon-Albright LA,Skolnick MH

    更新日期:1996-02-01 00:00:00

  • Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.

    abstract::This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Greco FA,Hainsworth JD

    更新日期:1994-10-01 00:00:00

  • Rituximab in chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) is the most common adult leukemia but is currently incurable by conventional therapeutic interventions. Rituximab has proven efficacy and tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in previously untreated or relapsed/refractory indolent non-Hodgki...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50033

    authors: Montserrat E

    更新日期:2003-02-01 00:00:00

  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

    abstract::A wide variety of cytogenetic abnormalities and molecular pathways have been implicated in the pathogenesis of sarcoma, and significant progress has been made in the past decade toward identifying potential therapeutic targets. However, apart from gastrointestinal stromal tumors (GISTs) and dermatofibrosarcoma protube...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.09.003

    authors: Riedel RF

    更新日期:2011-10-01 00:00:00

  • Metastatic breast cancer: preliminary results with oral hormonal therapy.

    abstract::Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

    更新日期:1985-12-01 00:00:00

  • Pharmacogenetics in esophageal cancer.

    abstract::The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.04.031

    authors: Wu X,Lu C,Chiang SS,Ajani JA

    更新日期:2005-12-01 00:00:00

  • The National Cancer Institute and Department of Veterans Affairs Interagency Group to Accelerate Trials Enrollment (NAVIGATE): A federal collaboration to improve cancer care.

    abstract::Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.005

    authors: Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

    更新日期:2019-01-01 00:00:00

  • Paclitaxel in the treatment of esophageal cancer.

    abstract::Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Weiner LM

    更新日期:1999-02-01 00:00:00

  • Mechanism of action of trastuzumab and scientific update.

    abstract::The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90276-3

    authors: Baselga J,Albanell J,Molina MA,Arribas J

    更新日期:2001-10-01 00:00:00

  • New perspectives on the toxicity of etoposide.

    abstract::Etoposide has been used in the treatment of a wide variety of neoplasms, including small cell lung cancer. Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kobayashi K,Ratain MJ

    更新日期:1992-12-01 00:00:00

  • Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.

    abstract::In vitro uptake and retention of 3H-cytosine arabinoside (ara-C) was studied in 68 acute myelogenous leukemia (AML) patients (ten were studied twice) treated with a regimen containing conventional (54 patients) or high doses (24) of ara-C. Drug uptake and retention after four hours were measured following 30 minutes e...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Zittoun R,Marie JP,Delanian S,Suberville AM,Thevenin D

    更新日期:1987-06-01 00:00:00

  • The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

    abstract::In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams SF

    更新日期:1990-02-01 00:00:00

  • Other options in the treatment of advanced breast cancer.

    abstract::Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.04.005

    authors: Cobleigh MA

    更新日期:2011-06-01 00:00:00

  • The role of interferon in the therapy of epidemic Kaposi's sarcoma.

    abstract::Kaposi's sarcoma (KS) is the major neoplastic complication of the acquired immune deficiency syndrome (AIDS). Although most patients succumb to infectious complications of AIDS rather than as a direct consequence of the tumor, KS may, in some cases, pursue an aggressive clinical course resulting in considerable morbid...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Krown SE

    更新日期:1987-06-01 00:00:00